Reid Johnstone, MD
Allergy & Immunology · Greenville, SCNPI 1013907260
Payments from drug & device makers
Across 644 payments — averaging $19.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- AstraZeneca$2K
- CSL Behring$2K
- GSK$1K
- Pfizer$1K
- Biocryst US Sales Co., LLC$890
- plus $3K from 31 others
What the payments were for
- Food & beverage$12,716100%
- Education$450%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 147 | $2,295 |
| AstraZeneca | 66 | $2,077 |
| CSL Behring | 86 | $1,713 |
| GSK | 81 | $1,295 |
| Pfizer | 63 | $1,029 |
| Biocryst US Sales Co., LLC | 41 | $890 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $642 |
| AbbVie | 22 | $446 |
| Novartis | 12 | $299 |
| Grifols USA, LLC | 17 | $292 |
| Pharming Healthcare, Inc. | 11 | $269 |
| Regeneron Healthcare Solutions, Inc. | 9 | $212 |
| LEO Pharma Inc. | 7 | $156 |
| Kaleo, Inc. | 6 | $124 |
| Hospira, Inc. | 5 | $122 |
| Amgen | 4 | $107 |
| Alk-abello, Inc | 5 | $94 |
| Ionis Pharmaceuticals, Inc. | 4 | $78 |
| Lilly USA, LLC | 3 | $74 |
| Galderma Laboratories, L.p. | 2 | $59 |
| Optinose US, Inc. | 4 | $54 |
| Genentech USA, Inc. | 3 | $50 |
| Boehringer Ingelheim | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 3 | $37 |
| Hikma Pharmaceuticals USA | 2 | $36 |
| Shire North American Group Inc | 2 | $32 |
| USWM, LLC | 1 | $30 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $27 |
| Cycle Pharmaceuticals Inc | 1 | $25 |
| GC Biopharma USA, Inc. | 1 | $24 |
| Bio Products Laboratory USA, Inc. | 1 | $24 |
| Merck | 1 | $22 |
| Incyte Corporation | 1 | $21 |
| Aerin Medical Inc. | 1 | $20 |
| Biocryst Pharmaceuticals, Inc. | 1 | $17 |
| Organon | 1 | $15 |
| Octapharma USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$748
- SYMBICORT$399
- BEVESPI AEROSPHERE$221
- BREZTRI AEROSPHERE$178
- DUPIXENT$124
- CIBINQO$124
- BREZTRI$122
- NUCALA$108
- TEZSPIRE$100
How this compares
$12,761 in reported general payments places this provider in the 65th percentile of 46 allergy & immunology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HaegardaC1 Esterase Inhibitor | 12 | $542,487 |
| Dupixent SyringeDupilumab | 101 | $428,734 |
| HyqviaIgg/Hyaluronidase,recombinant | 13 | $131,849 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 11 | $118,148 |
| NucalaMepolizumab | 14 | $51,747 |
| Dupixent PenDupilumab | 13 | $48,647 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $43,570 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $13,191 |
| Ipratropium Bromide | 226 | $9,942 |
| Arnuity ElliptaFluticasone Furoate | 40 | $9,279 |
| Wixela InhubFluticasone Propion/Salmeterol | 33 | $7,505 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $5,449 |
| Azelastine Hcl | 225 | $5,359 |
| DuleraMometasone/Formoterol | 11 | $4,710 |
| Epinephrine | 24 | $3,797 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHaegarda, Hizentra | $1,713 | $660,63523 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Hyqvia | $642 | $131,84913 claims |
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,295 | $117,787123 claims |
| AstraZenecaSymbicort | $2,077 | $5,44917 claims |
| MerckDulera | $22 | $4,71011 claims |
| Hikma Pharmaceuticals USAEpinephrine | $36 | $3,79724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 46 allergy & immunology providers in South Carolina.
Other allergy & immunology in Greenville
- Douglas JohnstonGreenville$1.3M
- James KuhlenGreenville$39K
- Dennis PaulkGreenville$26K
- Rudolph JohnstoneGreenville$10K
- Charles GreeneGreenville$9K
- Andrea LantzGreenville$9K
- Shiven PatelGreenville$7K
- Melissa AndersonGreenville$3K
- John PulciniGreenville$2K
- Erin MullaneyGreenville$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.